# Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial

> clinical trial · VERIFIED · 2026-08-03

Status: NOT_YET_RECRUITING · Sponsor: West China Hospital · Condition: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

- Company: West China Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07490990

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.